Search Within

Carol A Aghajanian

Formats
  1. Journal Article (325)
  2. Meeting Abstract (284)
  3. Review (3)
  4. Book Section (1)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (615)
  2. GDMT, Medicine (615)
  3. Gynecologic Medicine Service (615)
  4. Gynecology Disease Management Team (615)
  5. Solid Tumor Oncology Division (615)
  6. Surgery (229)

More Groups

People
  1. Nadeem Abu-Rustum (126)
  2. Paul Sabbatini (125)
  3. Alexia Iasonos (116)
  4. David Spriggs (105)
  5. Roisin O'Cearbhaill (99)
  6. Martee Hensley (94)

More People

Years
  1. 2025 (24)
  2. 2024 (38)
  3. 2023 (42)
  4. 2022 (45)
  5. 2021 (35)
  6. 2020 (61)

More Years

Publications
  1. Gynecologic Oncology (200)
  2. Journal of Clinical Oncology (150)
  3. International Journal of Gynecological Cancer (57)
  4. Clinical Cancer Research (30)
  5. Annals of Oncology (28)
  6. Cancer (15)

More Publications

Publishers
  1. Elsevier B.V. (204)
  2. American Society of Clinical Oncology (156)
  3. Lippincott Williams & Wilkins (59)
  4. American Association for Cancer Research (54)
  5. Oxford University Press (30)
  6. Elsevier Inc. (21)

More Publishers

Results (615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
    Journal Article

    Zammarrelli, W. A. 3rd; Ma, W.; Espino, K.; Gordhandas, S.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N. R.; Aghajanian, C.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Response to letter to the editor, Gilks et al
    Correspondence

    Weigelt, B.; Mueller, J. J.; Ellenson, L. H.; Abu-Rustum, N. R.; Aghajanian, C.
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Journal Article

    Pignata, S.; Bookman, M.; Sehouli, J.; Miller, A.; Penson, R. T.; Taskiran, C.; Anderson, C.; Hietanen, S.; Myers, T.; Madry, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Pathogenic germline variants in patients with endometrial cancer across diverse ancestries
    Meeting Abstract

    Liu, Y. L.; Gordhandas, S.; Arora, K.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E. E.; Zhou, Q.; Iasonos, A.; Selenica, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Ring, K. L.; Van Nieuwenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A.; Clamp, A. R.; Moore, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline variants in non- BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival
    Meeting Abstract

    Kahn, R. M.; Selenica, P.; Boerner, T.; Xiao, Y.; Sia, T.; Sheehan, M.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
    Meeting Abstract

    Leath, C. A.; Deng, W.; Mell, L. K.; Richardson, D. L.; Walker, J. L.; Holman, L. L.; Lea, J. S.; Amarnath, S. R.; Santos-Reyes, L. J.; Arend, R. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
    Meeting Abstract

    Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Overcoming barriers to tumor genomic profiling through direct-to-patient outreach
    Journal Article

    Doe-Tetteh, S. A.; Camp, S. Y.; Reales, D.; Crowdis, J.; Noronha, A. M.; Wolff, B.; Alano, T.; Galle, J.; Selcuklu, S. D.; Viale, A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies
    Journal Article

    Manning-Geist, B. L.; Kahn, R. M.; Nemirovsky, D.; Girshman, J.; Laibangyang, A.; Gordhandas, S.; Iasonos, A.; Chui, M. H.; Long Roche, K.; Zivanovic, O.; more...
    Cancer (2023)

    Fulltext@MSK | Save